AXEL HOFFMANN,HEINRICH LANNERT,KLAUS BRISCHWEIN,FREDERIC CHRISTIAN PIPP,JUERGEN REINDL,KARIN GROLL,MICHAEL ZUEHLSDORF,OTMAR PFAFF,SABINE RAAB,ULRIKE DAU,BENOIT DESTENAVES
申请号：
MX2013009062
公开号：
MX352025B
申请日:
2012.02.07
申请国别(地区):
MX
年份:
2017
代理人:
摘要：
The invention is directed to the treatment of prostate cancer by means of antibodies. Above all, the invention relates to the administration of an anti-alpha-v integrin (receptor) antibody to patients suffering from prostate cancer, especially castration- resistant prostate cancer (CRPC), optionally accompanied by lymph node and bone tissue metastases (mCRPC). In particular, the invention relates to the therapy of said patients by means of the anti-angiogenic antibody DI17E6 and structural mutants thereof.La presente invención se refiere a el uso de un anticuerpo anti-integrina avD117E6 en la elaboración de un medicamento para el tratamiento de un paciente que sufre de cáncer de próstata resistente a la castración (CRPC), en donde el anticuerpo anti-intregrina avD117E6 es administrable al paciente en una cantidad de 500 mg por dos semanas durante 4-8 meses.
